Sofosbuvir/Ribavirin/Epigallocatechin Gallate

索磷布韦/利巴韦林/表没食子儿茶素没食子酸酯

Report date: 2024/12/23 14:40:46

Base Information

Drug NameSofosbuvir/Ribavirin/Epigallocatechin Gallate

Drug Alias Name表没食子儿茶素没食子酸酯/利巴韦林/索磷布韦Epigallocatechin gallate/Ribavirin/SofosbuvirSofosbuvir/Ribavirin/(-)-Epigallocatechin gallateCatvira

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues

Mechanisms of ActionInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitorsmRNA guanylyltransferase inhibitorsHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors +[4]

TargetsInosine-5'-monophosphate dehydrogenase (IMPDH)Hepatitis C virus NS5B RNA-dependent RNA polymeraseBacterial DNA-directed RNA polymerase +[4]

Therapy Area/IndicationsHepatitis C

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsYes Ribavirin (-)-Epigallocatechin gallate Sofosbuvir

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesVirothera Pharmaceuticals

China Registration ClassN/A

Develop Information

Active CompaniesVirothera Pharmaceuticals The Egyptian Liver Research Institute And Hospital

Inactive CompaniesN/A

Active IndicationsHepatitis C

Inactive IndicationsN/A

Other Information

ATC CodeN/A